Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection
about
The endocannabinoid system as an emerging target of pharmacotherapyThe Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination.Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling.Intrinsic up-regulation of 2-AG favors an area specific neuronal survival in different in vitro models of neuronal damage.Cannabinoid control of neuroinflammation related to multiple sclerosis.The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.Multiple sclerosis may disrupt endocannabinoid brain protection mechanism.Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease.TNF-Α may mediate inflammasome activation in the absence of bacterial infection in more than one way.P2 receptors and immunity.Microglia produce and hydrolyze palmitoylethanolamide.An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.Targeting the CB2 receptor for immune modulation.Connexin 43 hemichannels are permeable to ATP.P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis.Synaptic P2X7 receptor regenerative-loop hypothesis for depression.Targeting the endocannabinoid system: to enhance or reduce?Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation.Endocannabinoid signaling in microglial cellsP2X(7) receptor at the heart of disease.DAGL-dependent endocannabinoid signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis.Cannabinoids, multiple sclerosis and neuroprotection.The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.Neurotransmitter signaling in the pathophysiology of microglia.Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions.Central nervous system myeloid cells as drug targets: current status and translational challenges.The microglial ATP-gated ion channel P2X7 as a CNS drug target.Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells.P2X(7) Receptors in Neurological and Cardiovascular Disorders.Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease.Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.
P2860
Q24648473-73493A4E-DA94-4546-B431-C0EEF441AEB8Q30370881-3D86C0A5-BA0E-4872-9133-75ABDC35D078Q33793559-7850B640-2474-451B-A139-A76C99E384DAQ34098196-B3771CD3-65DD-4B7B-8903-2C39487EE32AQ34328201-38CE9A72-2D0D-46B9-A489-24F293633D8CQ34531690-47BF8CDE-4F0F-4530-BF50-AE8E819F31E6Q34583231-4FC52DA4-B1E7-4620-BF76-2217F8F8F52FQ34589360-8D22D620-012C-4FDD-A5EC-2A23F30EA66CQ34597217-A65E5D3F-C34A-4EC9-A356-65B23588470DQ34664067-66BBE2C9-54EA-4056-9987-811149210F8BQ34937708-0E54A442-1E07-4CE0-8F81-9EB7278D7B62Q36446067-49A4AC45-B1C3-4409-BFB1-CF1FDDA8AABBQ36477987-91CC4B22-9091-4736-B488-1E8F089CC1B0Q36591816-9BDB2D42-55EE-43C7-9D29-B307E4C1909AQ36596663-338678C2-395B-473B-BE9C-552716A72D1AQ36803018-4B37AD24-BDCC-4A2C-8942-8552D70237CCQ36842750-226F8D36-B3C6-4CFD-B370-5A0E1AE1D17EQ36844826-39808046-E18F-412E-803E-FF3E89159486Q37150745-A13BCBA6-5B41-4306-AC3B-963E6F861825Q37246426-E2D99B95-5A44-4108-B54C-EDEE6F85E195Q37250243-AECDD02C-64DF-4C85-B4A6-04444E3FA777Q37803535-51330F95-C54C-4DA2-86E1-887CC1790358Q37958906-B1538363-B27A-48C2-88D0-9CC64EFEE637Q37960199-86BA5FBD-3B09-4EF1-ABEA-EEB2BA388E04Q38072364-FD320CCA-9D34-47E6-811D-7C9DBF28870BQ38102686-99868865-0844-4FFD-A746-E840ADF8A169Q38185071-3A0328DC-9BB3-4405-BDD3-57E5ECF70DF3Q38658658-6178F57D-0002-44B5-838C-307599341C63Q38843107-E041672E-5EAB-41CF-B80E-2A1E927F55B6Q39959642-81A19B46-C783-48C3-ABB2-C7517C3A61BEQ42265737-8859A955-DE0C-46ED-9665-05BB2B4AB757Q42487631-224B225B-93C3-4ED8-872A-B9CDA9CCF618Q55266660-7C892D46-C16E-4522-8BC1-65522545DA04
P2860
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@ast
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@en
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@nl
type
label
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@ast
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@en
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@nl
prefLabel
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@ast
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@en
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@nl
P2093
P2860
P356
P1476
Experimental autoimmune enceph ...... inoid-mediated neuroprotection
@en
P2093
Alex Straiker
Anke Witting
Barry Rickman
Celia Brosnan
Eiron Cudaback
Nephi Stella
Thomas Möller
P2860
P304
P356
10.1073/PNAS.0510418103
P407
P577
2006-03-29T00:00:00Z